BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 32531951)

  • 21. Androgen deprivation induces human prostate epithelial neuroendocrine differentiation of androgen-sensitive LNCaP cells.
    Yuan TC; Veeramani S; Lin FF; Kondrikou D; Zelivianski S; Igawa T; Karan D; Batra SK; Lin MF
    Endocr Relat Cancer; 2006 Mar; 13(1):151-67. PubMed ID: 16601285
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Transdifferentiation of prostate cancer cells to a neuroendocrine cell phenotype in vitro and in vivo.
    Burchardt T; Burchardt M; Chen MW; Cao Y; de la Taille A; Shabsigh A; Hayek O; Dorai T; Buttyan R
    J Urol; 1999 Nov; 162(5):1800-5. PubMed ID: 10524938
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Suppressive Effect of Delta-Tocotrienol on Hypoxia Adaptation of Prostate Cancer Stem-like Cells.
    Kaneko S; Sato C; Shiozawa N; Sato A; Sato H; Virgona N; Yano T
    Anticancer Res; 2018 Mar; 38(3):1391-1399. PubMed ID: 29491063
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The cannabinoid WIN 55,212-2 prevents neuroendocrine differentiation of LNCaP prostate cancer cells.
    Morell C; Bort A; Vara D; Ramos-Torres A; Rodríguez-Henche N; Díaz-Laviada I
    Prostate Cancer Prostatic Dis; 2016 Sep; 19(3):248-57. PubMed ID: 27324222
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Interleukin-6 induces VEGF secretion from prostate cancer cells in a manner independent of androgen receptor activation.
    Ishii K; Sasaki T; Iguchi K; Kajiwara S; Kato M; Kanda H; Hirokawa Y; Arima K; Mizokami A; Sugimura Y
    Prostate; 2018 Aug; 78(11):849-856. PubMed ID: 29707793
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Increased acid ceramidase expression depends on upregulation of androgen-dependent deubiquitinases, USP2, in a human prostate cancer cell line, LNCaP.
    Mizutani N; Inoue M; Omori Y; Ito H; Tamiya-Koizumi K; Takagi A; Kojima T; Nakamura M; Iwaki S; Nakatochi M; Suzuki M; Nozawa Y; Murate T
    J Biochem; 2015 Oct; 158(4):309-19. PubMed ID: 25888580
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Independence of HIF1a and androgen signaling pathways in prostate cancer.
    Tran MGB; Bibby BAS; Yang L; Lo F; Warren AY; Shukla D; Osborne M; Hadfield J; Carroll T; Stark R; Scott H; Ramos-Montoya A; Massie C; Maxwell P; West CML; Mills IG; Neal DE
    BMC Cancer; 2020 May; 20(1):469. PubMed ID: 32450824
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term exposure of tumor necrosis factor alpha causes hypersensitivity to androgen and anti-androgen withdrawal phenomenon in LNCaP prostate cancer cells.
    Harada S; Keller ET; Fujimoto N; Koshida K; Namiki M; Matsumoto T; Mizokami A
    Prostate; 2001 Mar; 46(4):319-26. PubMed ID: 11241555
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Wnt-11 promotes neuroendocrine-like differentiation, survival and migration of prostate cancer cells.
    Uysal-Onganer P; Kawano Y; Caro M; Walker MM; Diez S; Darrington RS; Waxman J; Kypta RM
    Mol Cancer; 2010 Mar; 9():55. PubMed ID: 20219091
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Chronic hypoxia-induced slug promotes invasive behavior of prostate cancer cells by activating expression of ephrin-B1.
    Iwasaki K; Ninomiya R; Shin T; Nomura T; Kajiwara T; Hijiya N; Moriyama M; Mimata H; Hamada F
    Cancer Sci; 2018 Oct; 109(10):3159-3170. PubMed ID: 30058095
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The adrenal androgen androstenediol is present in prostate cancer tissue after androgen deprivation therapy and activates mutated androgen receptor.
    Mizokami A; Koh E; Fujita H; Maeda Y; Egawa M; Koshida K; Honma S; Keller ET; Namiki M
    Cancer Res; 2004 Jan; 64(2):765-71. PubMed ID: 14744796
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Androgen glucuronidation: an unexpected target for androgen deprivation therapy, with prognosis and diagnostic implications.
    Grosse L; Pâquet S; Caron P; Fazli L; Rennie PS; Bélanger A; Barbier O
    Cancer Res; 2013 Dec; 73(23):6963-71. PubMed ID: 24121496
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lineage plasticity-mediated therapy resistance in prostate cancer.
    Blee AM; Huang H
    Asian J Androl; 2019; 21(3):241-248. PubMed ID: 29900883
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Acquisition of agonistic properties of nonsteroidal antiandrogens after treatment with oncostatin M in prostate cancer cells.
    Godoy-Tundidor S; Hobisch A; Pfeil K; Bartsch G; Culig Z
    Clin Cancer Res; 2002 Jul; 8(7):2356-61. PubMed ID: 12114440
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Human ASH-1 promotes neuroendocrine differentiation in androgen deprivation conditions and interferes with androgen responsiveness in prostate cancer cells.
    Rapa I; Volante M; Migliore C; Farsetti A; Berruti A; Vittorio Scagliotti G; Giordano S; Papotti M
    Prostate; 2013 Aug; 73(11):1241-9. PubMed ID: 23657976
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Androgens up-regulate the insulin-like growth factor-I receptor in prostate cancer cells.
    Pandini G; Mineo R; Frasca F; Roberts CT; Marcelli M; Vigneri R; Belfiore A
    Cancer Res; 2005 Mar; 65(5):1849-57. PubMed ID: 15753383
    [TBL] [Abstract][Full Text] [Related]  

  • 37. 1alpha,25-dihydroxyvitamin D3 actions in LNCaP human prostate cancer cells are androgen-dependent.
    Zhao XY; Ly LH; Peehl DM; Feldman D
    Endocrinology; 1997 Aug; 138(8):3290-8. PubMed ID: 9231780
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Interleukin-6/signal transducer and activator of transcription 3 promotes prostate cancer resistance to androgen deprivation therapy via regulating pituitary tumor transforming gene 1 expression.
    Huang S; Liu Q; Liao Q; Wu Q; Sun B; Yang Z; Hu X; Tan M; Li L
    Cancer Sci; 2018 Mar; 109(3):678-687. PubMed ID: 29288516
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Resveratrol inhibits hypoxia-inducible factor-1α-mediated androgen receptor signaling and represses tumor progression in castration-resistant prostate cancer.
    Mitani T; Harada N; Tanimori S; Nakano Y; Inui H; Yamaji R
    J Nutr Sci Vitaminol (Tokyo); 2014; 60(4):276-82. PubMed ID: 25297617
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Development of an androgen-deprivation induced and androgen suppressed human prostate cancer cell line.
    Lee SO; Dutt SS; Nadiminty N; Pinder E; Liao H; Gao AC
    Prostate; 2007 Sep; 67(12):1293-300. PubMed ID: 17626246
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.